Myanmar Has No Dedicated Medical Device Act

1. Key takeaways

Myanmar has not yet enacted a dedicated medical device law. This is the first fact that must be accepted before entering the Myanmar market, and it is the starting point of all compliance work. The current rules do not come from a unified device code; they are assembled from three layers: the technical layer is the ASEAN Medical Device Directive (AMDD, 2015); the procedural layer consists of administrative guidance and technical guidelines issued from time to time by the Myanmar Food and Drug Administration (FDA); and the authorisation layer is the general enforcement authority of the Public Health Law 1972.

• Because no Medical Device Law has been implemented in Myanmar, the Myanmar FDA applies the ASEAN Medical Device Directive together with its administrative guidance issued from time to time, as reported in the Myanmar chapter of the International Bar Association (IBA) Medical and Healthcare Survey 2024.
• A draft harmonised medical device law aligned with the AMDD has been submitted to the Attorney General’s Office; after approval it must still be submitted to the Myanmar Parliament for comments.
• The enforcement authority rests on section 3(3)(d) of the Public Health Law 1972, which the state newspaper Global New Light of Myanmar has cited directly when reporting FDA announcements on unregistered cosmetics.
• The National Drug Law of 1992 (Law No. 7 of 1992), the only legislation in force according to the US Department of Commerce export.gov Myanmar medical page, does not cover medical devices.
• Key dates: the AMDD was adopted in 2015; Myanmar deposited its instrument of acceptance in July 2018; the harmonisation timeline is 5 years, counted from 2016.
• Compliance certainty in Myanmar is markedly lower than in ASEAN markets that have completed dedicated legislation, so tracking Myanmar FDA announcements should be established as a standing function, not a one-off action.

2. Legal basis

The table below consolidates the legal and administrative instruments that together define the Myanmar regulatory framework for medical devices. Because there is no dedicated device statute, each row represents one layer of the assembled framework, and the sources must be read together rather than in isolation.

3. Expert insights

Insight 1: no dedicated law does not mean no regulation; it means the rules are stored elsewhere. Myanmar’s rules are stored in administrative guidance, technical guidelines and case-by-case review practices, rather than in a codified statute. The direct consequence is that retrieval difficulty rises, the frequency of changing interpretations rises, and the citability of written bases declines. Companies should record the type of information source (statute, administrative guidance, technical guideline, or case-by-case interpretation) in internal compliance documents, instead of labelling everything uniformly as regulatory requirements.

Insight 2: the three layers each have a distinct role, and none can be missing. The AMDD supplies the technical logic of the A–D risk classification and conformity assessment; FDA administrative guidance and technical guidelines supply procedural rules and document formats; and the Public Health Law 1972 supplies enforcement power. Without any one layer the rules cannot operate, which also explains why Myanmar has been able to keep a device registration system running in the absence of a dedicated law.

Insight 3: the legislative process has advanced continuously since 2018 but has not yet landed. The draft dedicated law has been submitted to the Attorney General’s Office and, once approved, must still go to Parliament. When planning over the medium to long term, companies must build in the variable that a dedicated law may be enacted within the planning horizon, and should pre-arrange regulatory-change clauses in authorised representative agreements.

Insight 4: compared with ASEAN markets that have completed legislation, the shape of compliance risk in Myanmar is different. In markets such as Singapore, Malaysia and Thailand the main risk is whether the technical documentation meets the standard; in Myanmar the risk is that the rules themselves may change. The former can be controlled through documentation quality, while the latter can only be managed through information tracking and contractual flexibility.

Insight 5: the existence of a residual enforcement provision gives enforcement legal certainty. Even without a dedicated law, section 3(3)(d) provides an explicit enforcement authority. This means that the absence of a dedicated law is no defence.

4. Practical recommendations

• Make tracking Myanmar FDA announcements a standing function. Assign a named person to search the FDA website and the e-Submission portal announcement columns monthly, and retain the search records.
• Label the hierarchy of information sources in internal compliance documents. Distinguish statutory provisions, administrative guidance, technical guidelines and case-by-case interpretations, and avoid presenting administrative guidance as legal requirements.
• Pre-arrange regulatory-change clauses in authorised representative agreements. Agree in advance on responsibility for supplementary documentation, cost allocation and timelines once a dedicated law is enacted.
• Do not omit compliance actions on the ground that no statute exists. The residual enforcement provision gives enforcement a sufficient legal basis.
• Maintain dual-track contingency plans for the possible enactment of a dedicated law. Prepare a dossier structure that can be expanded quickly to higher documentation requirements.

5. Verification checklist

• □ Confirmed that Myanmar has not yet enacted a dedicated medical device law (IBA 2024 survey)
• □ Confirmed that the draft dedicated law has been submitted to the Attorney General’s Office and, after approval, must still be submitted to Parliament
• □ Recorded section 3(3)(d) of the Public Health Law 1972 as the anchor of enforcement authority
• □ Confirmed that the National Drug Law (Law No. 7 of 1992) does not cover medical devices
• □ Established a monthly tracking mechanism for Myanmar FDA announcements
• □ Distinguished statutes, administrative guidance, technical guidelines and case-by-case interpretations in internal documents
• □ Included regulatory-change response clauses in authorised representative agreements

Regulatory information verified as of 29 October 2026.

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support across Southeast Asia, including Myanmar. Our team prepares the technical dossier to ASEAN CSDT structure, manages submission and deficiency responses with the Myanmar FDA, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com